Acquires Swiss-based Senn Chemicals
Granules India announced the signing of the acquisition agreement regarding Senn Chemicals, a Swiss-based CDMO specialising in peptides. Senn develops and manufactures, peptides and peptides-based applications for its global customers, providing contract research, development, and manufacturing services. The closing of the acquisition is subject to certain conditions. The closing is expected to occur in the first half of 2025.
The acquisition brings Senn’s expertise in Liquid-Phase Peptide Synthesis (LPPS) and Solid-Phase Peptide Synthesis (SPPS), along with a strong CDMO business and established customer relationships, including innovators and brand owners across pharma, cosmetics, amino acid derivatives (AAD) and theragnostic segments.
The acquisition enables Granules’ acquisition capabilities into high-growth peptide-based therapeutics. The acquisition aligns with Granules’ vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market, including GLP-1 receptor agonists and other next-generation therapeutics. Granules and Senn have been developing two GLP-1-based APIs and both projects are progressing well. More peptide-based APIs are planned to be added to the portfolio and developed using Senn’s R&D capabilities.
The acquisition marks Granules foray into CDMO segments, leveraging Senn’s existing CDMO business and customer relationships, on the back of its R&D and manufacturing platform. With this transaction, Granules will leverage Senn’s European presence and innovation-driven peptide platform to accelerate its CDMO expansion and meet the fast-growing demand for Amino Acid Derivative (AAD), peptide fragments, and peptide-based therapeutics. Senn presence in Europe, provides access to a skilled R&D talent pool and regulated market clients, further strengthening Granules’ global footprint.
By integrating Senn’s capabilities with Granules’ expertise in large-scale, cost-efficient manufacturing, Granules aims to become a key player in the development and manufacturing of peptide-based applications across Pharmaceuticals, cosmetics and theragnostic segments industries, spanning the entire value chain from AADs and Peptide fragments to peptide-based active ingredients.
Dr Krishna Prasad Chigurupati, CMD, Granules India, said, "By entering the rapidly growing peptide therapeutics segment and acquiring CDMO capabilities, we are expanding into next-generation therapeutics that align with our commitment to innovation and affordability. Senn’s expertise in peptide synthesis, coupled with our large-scale, cost-efficient manufacturing capabilities, positions us to deliver high-quality peptide-based solutions globally. This acquisition is a pivotal moment in our vision to transform Granules into a science and innovation-led organization and become a trusted partner in complex and specialised therapeutics."
Dr Rico Wiedenbruch, Chairman, Senn Chemicals, said "We are excited to join forces with Granules India, a company that shares our commitment to scientific excellence and customer-centric innovation. With Granules’ scale, operational efficiency, and global reach in the pharmaceutical industry, we see strategic fit and tremendous potential to accelerate our growth and expand our capabilities in rapidly growing peptide therapeutics. This partnership strengthens our ability to serve our customers with best-in-class CDMO solutions while driving innovation in peptide development and manufacturing."
